Compound Evidence File
#EC-2026-0082
Ipamorelin(GHS agonist)
Filed under Peptides. The bureau holds 348 laboratory returns for this compound from 77 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
77 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 10.0 | 9.9 | 10.0 | 11 Apr 2026 | 28 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 10.0 | 9.9 | 10.0 | 26 Feb 2026 | 1 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 10.0 | 9.9 | 10.0 | 19 Jan 2026 | 22 May 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 10.0 | 9.9 | 10.0 | 14 Dec 2025 | 20 Jun 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 10.0 | 9.9 | 10.0 | 9 May 2026 | 11 Aug 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 4 | 10.0 | 10.0 | 10.0 | 7 Jan 2026 | 28 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 10.0 | 9.9 | 10.0 | 21 Dec 2025 | 16 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 3 | 10.0 | 9.9 | 10.0 | 6 Feb 2026 | 22 Jun 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 10.0 | 10.0 | 10.0 | 23 Feb 2026 | 10 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 10.0 | 10.0 | 10.0 | 22 Feb 2026 | 4 Apr 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 10.0 | 10.0 | 10.0 | 13 Feb 2026 | 25 May 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 10.0 | 10.0 | 10.0 | 1 Jan 2026 | 3 May 2026 |
| Peptide PartnersCASE #VI-2026-0295 | A | 7 | 9.9 | 9.4 | 10.0 | 23 Oct 2025 | 20 May 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 7 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 4 | 9.9 | 9.9 | 10.0 | 2 Feb 2026 | 19 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 9.9 | 9.9 | 10.0 | 18 Feb 2026 | 2 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 8 Apr 2026 | 19 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 9.9 | 9.9 | 10.0 | 12 Mar 2026 | 28 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 9.9 | 9.9 | 9.9 | 22 May 2026 | 21 Jun 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 3 | 9.9 | 9.9 | 10.0 | 22 May 2026 | 6 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 4 Mar 2026 | 26 May 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 10.0 | 26 Apr 2026 | 1 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 9.9 | 9.9 | 10.0 | 9 Apr 2026 | 11 Jul 2026 |
| InjectifyCASE #VI-2026-0387 | A | 4 | 9.3 | 7.9 | 10.0 | 16 May 2025 | 5 Sep 2025 |
| Peptide SciencesCASE #VI-2026-0867 | A | 9 | 9.2 | 6.9 | 10.0 | 13 Feb 2025 | 20 May 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 2 | 9.2 | 8.7 | 9.7 | 21 May 2026 | 21 May 2026 |
| Planet PeptideCASE #VI-2026-0092 | A | 4 | 8.7 | 6.4 | 9.7 | 13 Feb 2025 | 19 Feb 2025 |
| Yiwu Aozuo Trading CoCASE #VI-2026-0798 | A | 6 | 8.6 | 6.5 | 10.0 | 9 Jun 2025 | 24 May 2026 |
| Accelerate LabsCASE #VI-2026-0686 | A | 3 | 8.6 | 7.0 | 9.6 | 16 May 2025 | 6 Sep 2025 |
| NUPEPS PeptidesCASE #VI-2026-0896 | A | 2 | 8.6 | 8.0 | 9.2 | 16 Dec 2025 | 18 Dec 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 8 | 8.5 | 7.2 | 9.3 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 7 | 8.4 | 6.9 | 9.6 | 23 May 2026 | 23 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 5 | 8.4 | 7.1 | 10.0 | 21 May 2026 | 21 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 5 | 8.4 | 6.0 | 9.9 | 24 May 2026 | 24 May 2026 |
| Paramount PeptidesCASE #VI-2026-0550 | A | 7 | 8.2 | 6.5 | 9.5 | 27 Feb 2025 | 5 May 2025 |
| Reta-PeptideCASE #VI-2026-0756 | B | 7 | 8.2 | 5.2 | 9.8 | 24 Jul 2025 | 24 May 2026 |
| Mai PeptideCASE #VI-2026-0769 | C | 6 | 8.1 | 4.8 | 9.9 | 21 Aug 2025 | 21 May 2026 |
| NextechLabsCASE #VI-2026-0285 | A | 4 | 7.9 | 6.4 | 9.9 | 27 Feb 2025 | 20 Mar 2025 |
| HK PeptidesCASE #VI-2026-0140 | C | 13 | 7.9 | 4.8 | 10.0 | 21 Aug 2025 | 23 May 2026 |
| Astro PeptidesCASE #VI-2026-0424 | A | 7 | 7.7 | 6.2 | 9.8 | 22 Apr 2025 | 5 May 2025 |
| Bulk Peptide WholesaleCASE #VI-2026-0319 | A | 3 | 7.7 | 6.5 | 9.3 | 25 Nov 2025 | 21 May 2026 |
| Prime PeptidesCASE #VI-2026-0696 | A | 5 | 7.6 | 6.2 | 9.0 | 16 May 2025 | 13 Jun 2025 |
| LiliPeptideCASE #VI-2026-0695 | D | 7 | 7.6 | 3.5 | 10.0 | 25 Sep 2025 | 19 May 2026 |
| Precision Peptide CoCASE #VI-2026-0559 | B | 4 | 7.5 | 6.0 | 8.6 | 7 May 2025 | 16 May 2025 |
| Peptide-SCASE #VI-2026-0111 | B | 4 | 7.5 | 5.8 | 9.9 | 5 Aug 2025 | 21 May 2026 |
| UtherCASE #VI-2026-0902 | D | 5 | 7.4 | 3.3 | 10.0 | 9 Oct 2025 | 19 May 2026 |
| OupeptideCASE #VI-2026-0435 | A | 7 | 7.3 | 6.3 | 8.0 | 21 Aug 2025 | 26 Jan 2026 |
| ZLZ PeptideCASE #VI-2026-0524 | A | 6 | 7.3 | 6.4 | 8.0 | 3 Oct 2025 | 26 Jan 2026 |
| Biolongevity LabsCASE #VI-2026-0442 | A | 4 | 7.3 | 6.3 | 8.0 | 16 May 2025 | 25 Jun 2025 |
| Weifang Xingbei International TradeCASE #VI-2026-0766 | X | 1 | 7.3 | 7.3 | 7.3 | 25 May 2026 | 25 May 2026 |
| Simple PeptideCASE #VI-2026-0782 | A | 3 | 7.1 | 6.2 | 8.5 | 25 Apr 2025 | 30 Apr 2025 |
| Suaway Lab ResearchCASE #VI-2026-0488 | C | 5 | 7.1 | 5.0 | 8.0 | 1 Apr 2025 | 7 May 2025 |
| PeptidologyCASE #VI-2026-0520 | B | 3 | 6.9 | 6.3 | 7.2 | 16 May 2025 | 6 Aug 2025 |
| Atomik LabzCASE #VI-2026-0327 | C | 5 | 6.7 | 4.4 | 8.4 | 5 May 2025 | 25 Sep 2025 |
| Peptide CraftersCASE #VI-2026-0994 | B | 4 | 6.5 | 6.1 | 7.2 | 27 Feb 2025 | 20 Mar 2025 |
| Qing Li PeptideCASE #VI-2026-0469 | E | 12 | 6.5 | 3.0 | 9.5 | 10 Jun 2025 | 25 May 2026 |
| Skye PeptidesCASE #VI-2026-0451 | B | 5 | 6.4 | 5.4 | 7.7 | 27 Feb 2025 | 17 May 2026 |
| Zhejiang Yichenkang BiotechnologyCASE #VI-2026-0269 | C | 6 | 5.9 | 4.1 | 8.0 | 10 Jun 2025 | 5 Sep 2025 |
| PeptiLab ResearchCASE #VI-2026-0267 | C | 3 | 5.9 | 4.9 | 7.9 | 25 Apr 2025 | 5 May 2025 |
| Amino AsylumCASE #VI-2026-0828 | C | 2 | 5.9 | 4.2 | 7.7 | 19 Feb 2025 | 19 Feb 2025 |
| Alpha-GenCASE #VI-2026-0905 | E | 5 | 5.8 | 1.9 | 7.2 | 24 Apr 2025 | 20 May 2025 |
| NexaphCASE #VI-2026-0944 | E | 9 | 5.7 | 0.0 | 8.6 | 3 Jul 2025 | 20 May 2026 |
| Platinum CryoCASE #VI-2026-0406 | C | 6 | 5.6 | 4.8 | 6.5 | 22 Apr 2025 | 7 May 2025 |
| Verified PeptidesCASE #VI-2026-0407 | C | 4 | 5.6 | 4.9 | 6.9 | 13 Feb 2025 | 19 Feb 2025 |
| LN PeptidesCASE #VI-2026-0781 | X | 1 | 5.6 | 5.6 | 5.6 | 25 Sep 2025 | 25 Sep 2025 |
| Pure RawzCASE #VI-2026-0767 | D | 5 | 5.0 | 3.8 | 6.3 | 5 May 2025 | 3 Jun 2025 |
| Swiss ChemsCASE #VI-2026-0030 | D | 4 | 4.5 | 4.2 | 5.0 | 2 Apr 2025 | 5 May 2025 |
| Peptides 4 ResearchCASE #VI-2026-0511 | D | 4 | 4.4 | 3.2 | 5.0 | 7 May 2025 | 20 May 2025 |
| Nuscience PeptidesCASE #VI-2026-0554 | D | 2 | 4.3 | 4.2 | 4.5 | 7 May 2025 | 7 May 2025 |
| Limitless Life NootropicsCASE #VI-2026-0980 | D | 4 | 4.1 | 4.0 | 4.3 | 13 Feb 2025 | 19 Feb 2025 |
| PurePeptidesCASE #VI-2026-0234 | E | 4 | 3.6 | 3.5 | 3.7 | 27 Feb 2025 | 20 Mar 2025 |
| TydesCASE #VI-2026-0493 | X | 1 | 3.2 | 3.2 | 3.2 | 5 Mar 2025 | 5 Mar 2025 |
| Peptides For SaleCASE #VI-2026-0614 | E | 4 | 3.0 | 2.3 | 3.3 | 27 Feb 2025 | 20 Mar 2025 |
| Peptide GurusCASE #VI-2026-0854 | E | 7 | 2.7 | 2.0 | 3.1 | 20 Mar 2025 | 14 May 2025 |
| DeuschemCASE #VI-2026-0004 | E | 5 | 2.3 | 0.0 | 5.4 | 16 Jun 2025 | 6 Nov 2025 |
| Biolabshop LimitedCASE #VI-2026-0832 | E | 2 | 1.5 | 1.0 | 2.0 | 13 Jun 2025 | 5 Sep 2025 |
Open any subject to view the batch-level evidence for Ipamorelin(GHS agonist) alone.